Please login to the form below

Not currently logged in
Email:
Password:

Dr Georg Buchner joins Silence Therapeutics

He assumes a business development role at the London-based biotech

London-based biotech Silence Therapeutics has appointed Dr Georg Buchner VP, business development.

He was formerly VP of Corporate & Business Development at Novacta Biosystems and prior to that served as business development director at Haptogen. During that time he was instrumental in the sale of the Haptogen business to Wyeth, now part of Pfizer, in 2007

At Silence Georg will work with Tony Sedgwick, who was appointed chief business officer in September, as part of the company's strategy to continue to broaden its collaborations with global pharmaceutical and biotechnology companies.

Silence's CEO Thomas Christély said: "We are pleased to welcome Dr Georg Buchner to Silence. Georg has a strong track record in business development and his experience will strengthen our growing business development team as we seek to expand our increasing list of corporate partnerships.”

10th November 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics